AIDS researchers are investigating new vaccines that would prevent infection with HIV and reduce the spread of AIDS. Some have argued that product liability concerns have discouraged investment in HIV vaccine research and development. The purpose of this OTA background paper is to describe the current state of development of HIV vaccines, and to discuss what is known about adverse reactions that may occur. The background paper provides an overview of ethical issues that arise in the conduct of HIV vaccine trials. The report also discusses alternatives to the current product liability system to encourage the development of HIV vaccines and to fairly compensate those who are harmed as a result of adverse reactions to the vaccine. This background paper was prepared in response to a request from the Subcommittee on Health of the House Ways and Means Committee. It is eleventh in OTA's series of studies on HIV-related issues.Current HIV vaccine research is both exciting and frustrating because so much has been learned yet progress toward an effective vaccine has been so slow. If a private company does not believe that research can identify an adequate vaccine candidate over the next decade, or if ... them to the predicted costs of development and marketing, and the potential profits from alternative investments . ... It may also exist in the acarriage tradea in other countries (like Thailand, India, and Egypt).
|Title||:||Adverse reactions to HIV vaccines : medical, ethical, and legal issues.|
|Publisher||:||DIANE Publishing - 1995|